News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
206,150 Results
Type
Article (19810)
Company Profile (116)
Press Release (186216)
Multimedia
Podcasts (36)
Webinars (15)
Section
Business (63657)
Career Advice (833)
Deals (8988)
Drug Delivery (78)
Drug Development (18706)
Employer Resources (145)
FDA (3364)
Job Trends (6071)
News (95011)
Policy (7086)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1504)
Academic (2)
Accelerated approval (9)
Adcomms (16)
Allergies (31)
Alliances (17372)
ALS (55)
Alzheimer's disease (679)
Antibody-drug conjugate (ADC) (108)
Approvals (3478)
Artificial intelligence (260)
Autoimmune disease (58)
Automation (23)
Bankruptcy (51)
Best Places to Work (4885)
BIOSECURE Act (12)
Biosimilars (68)
Biotechnology (64)
Bladder cancer (48)
Brain cancer (16)
Breast cancer (198)
Cancer (1390)
Cardiovascular disease (155)
Career advice (751)
Career pathing (37)
CAR-T (101)
CDC (19)
Cell therapy (268)
Cervical cancer (10)
Clinical research (15224)
Collaboration (774)
Compensation (174)
Complete response letters (15)
COVID-19 (1005)
CRISPR (52)
C-suite (509)
Cystic fibrosis (53)
Data (1956)
Decentralized trials (1)
Denatured (23)
Depression (49)
Diabetes (137)
Diagnostics (2479)
Digital health (18)
Diversity (10)
Diversity, equity & inclusion (37)
Drug discovery (127)
Drug pricing (58)
Drug shortages (4)
Duchenne muscular dystrophy (79)
Earnings (15447)
Editorial (22)
Employer branding (23)
Employer resources (123)
Events (31095)
Executive appointments (574)
FDA (4257)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (6)
Frontotemporal dementia (6)
Funding (719)
Gene editing (91)
Generative AI (28)
Gene therapy (197)
GLP-1 (354)
Government (1403)
Guidances (121)
Healthcare (4946)
HIV (32)
Huntington's disease (23)
IgA nephropathy (23)
Immunology and inflammation (58)
Immuno-oncology (12)
Indications (31)
Infectious disease (1106)
Inflammatory bowel disease (78)
Inflation Reduction Act (8)
Influenza (41)
Intellectual property (66)
Interviews (119)
IPO (3640)
IRA (17)
Job creations (1312)
Job search strategy (638)
JPM (27)
Kidney cancer (2)
Labor market (83)
Layoffs (200)
Leadership (19)
Legal (1186)
Liver cancer (27)
Longevity (10)
Lung cancer (176)
Lymphoma (154)
Machine learning (19)
Management (43)
Manufacturing (319)
MASH (33)
Medical device (2672)
Medtech (2691)
Mergers & acquisitions (5757)
Metabolic disorders (352)
Multiple sclerosis (73)
NASH (9)
Neurodegenerative disease (126)
Neuropsychiatric disorders (21)
Neuroscience (1131)
Neurotech (1)
NextGen: Class of 2026 (2082)
Non-profit (1690)
Now hiring (67)
Obesity (179)
Opinion (129)
Ovarian cancer (36)
Pain (69)
Pancreatic cancer (48)
Parkinson's disease (88)
Partnered (21)
Patents (103)
Patient recruitment (120)
Peanut (16)
People (28055)
Pharmaceutical (25)
Pharmacy benefit managers (2)
Phase 1 (4467)
Phase 2 (6276)
Phase 3 (6028)
Pipeline (1608)
Policy (104)
Postmarket research (556)
Preclinical (2550)
Press Release (61)
Prostate cancer (67)
Psychedelics (27)
Radiopharmaceuticals (69)
Rare diseases (265)
Real estate (2555)
Recruiting (59)
Regulatory (5715)
Reports (40)
Research institute (1303)
Resumes & cover letters (108)
Rett syndrome (3)
RNA editing (9)
RSV (43)
Schizophrenia (56)
Series A (132)
Series B (91)
Service/supplier (7)
Sickle cell disease (39)
Special edition (11)
Spinal muscular atrophy (56)
Sponsored (18)
Startups (2016)
State (1)
Stomach cancer (6)
Supply chain (39)
Tariffs (16)
The Weekly (13)
Vaccines (311)
Venture capital (62)
Weight loss (108)
Women's health (39)
Worklife (18)
Date
Today (60)
Last 7 days (196)
Last 30 days (851)
Last 365 days (9615)
2026 (1352)
2025 (9650)
2024 (11388)
2023 (12949)
2022 (15524)
2021 (17636)
2020 (16244)
2019 (14946)
2018 (10795)
2017 (10275)
2016 (10148)
2015 (10839)
2014 (7987)
2013 (6913)
2012 (7343)
2011 (7527)
2010 (7015)
Location
Africa (330)
Alabama (34)
Alaska (4)
Arizona (91)
Arkansas (4)
Asia (11623)
Australia (2023)
California (3317)
Canada (1073)
China (301)
Colorado (167)
Connecticut (107)
Delaware (180)
Europe (30288)
Florida (500)
Georgia (95)
Hawaii (2)
Idaho (12)
Illinois (223)
India (38)
Indiana (271)
Iowa (12)
Japan (176)
Kansas (44)
Kentucky (12)
Louisiana (8)
Maine (7)
Maryland (323)
Massachusetts (2745)
Michigan (130)
Minnesota (173)
Mississippi (5)
Missouri (47)
Montana (5)
Nebraska (10)
Nevada (23)
New Hampshire (16)
New Jersey (1007)
New Mexico (16)
New York (1127)
North Carolina (549)
North Dakota (9)
Northern California (1708)
Ohio (113)
Oklahoma (9)
Oregon (20)
Pennsylvania (550)
Puerto Rico (7)
Rhode Island (16)
South America (393)
South Carolina (8)
Southern California (1152)
Tennessee (64)
Texas (460)
United States (12493)
Utah (73)
Vermont (1)
Virginia (86)
Washington D.C. (32)
Washington State (263)
West Virginia (1)
Wisconsin (79)
Wyoming (1)
206,150 Results for "myovant sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Sumitovant Biopharma Completes Acquisition of Myovant Sciences
Sumitovant Biopharma Ltd. (“Sumitovant”) and Myovant Sciences Ltd. (“Myovant”) announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.
March 10, 2023
·
5 min read
Biotech Bay
Myovant Sciences to Participate at Upcoming September 2022 Investor Conferences
Myovant Sciences announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and Uneek Mehra, Chief Financial and Business Officer, will participate in the following upcoming investor conferences.
September 2, 2022
·
2 min read
gene therapy
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just as regulatory and government policies spark momentum and frustration.
January 28, 2026
·
4 min read
·
Heather McKenzie
Job Trends
BioSpace
Reveals Fresh Design With 2026 Hotbed Maps, Highlighting Life Sciences Hubs
BioSpace
has revealed its new 2026 Hotbed Maps, showcasing seven regional life sciences hot spots.
January 20, 2026
·
2 min read
·
Chantal Dresner
Business
Myovant Sciences Cancels Second Quarter Earnings Conference Call
Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time.
October 24, 2022
·
1 min read
Business
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources.
November 16, 2022
·
3 min read
Press Releases
Digital Disruption in Life Sciences: L7 Informatics Says Competitive Advantage Will Come From Governed Execution
L7 Informatics CEO explains why the next wave of life sciences innovation depends on digital unified platforms that orchestrate workflows, contextualize data, and enable AI-actionable operations.
February 12, 2026
·
1 min read
Biotech Bay
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., and Myovant Sciences announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
October 23, 2022
·
11 min read
Business
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the third quarter of fiscal year 2022 and provided other corporate updates.
January 26, 2023
·
21 min read
Biotech Bay
Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids
As part of National Women’s Health Week, Evidation and Myovant Sciences Ltd., a wholly owned subsidiary of Sumitovant Biopharma Ltd. announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
May 17, 2023
·
7 min read
1 of 20,615
Next
